Table 1. Characteristics of study subjects with primary HIV-1 infection evaluated for drug resistance mutations.
| No mutations | Mutations by OLA only | Mutations by CS | All Subjects | |||
| n = 72 | n = 22 | n = 5 | n = 99 | |||
| Age (median, IQR) | 34 (30–38) | 37 (30–43) | 33 (33–41) | 34 (30–40) | NS | |
| Caucasian, non-Hispanic | 92% | 95% | 100% | 93% | NS | |
| Days from infection to screening (median, IQR) | 22 (13–52) | 32 (24–63) | 54 (34–80) | 27 (15–63) | p = .05 | |
| CD4+ T-cell count at first visit (median cells/mm3, IQR) | 494 (386–678) | 551 (394–700) | 421 (396–550) | 496 (392–694) | NS* | |
| HIV RNA level at first visit (median log10 copies/mL, IQR) | 5.4 (4.5–6.2) | 5.1 (4.6–5.5) | 5.2 (5.0–6.0) | 5.2 (4.5–6.0) | NS* | |
| Median date of HIV infection (IQR) | 8/01 (1/00-1/04) | 4/02 (4/01-1/04) | 1/02 (8/00-4/04) | 11/01 (4/00-2/04) | NS | |
| Received ARV treatment | 64 (89%) | 20 (91%) | 5 (100%) | 89 (90%) | NS | |
| PI/NRTI | 26 (41%) | 7 (35%) | 2 (40%) | 35 (39%) | NS | |
| Initial | NNRTI /NRTI | 24 (38%) | 9 (45%) | 2 (40%) | 35 (39%) | |
| ARV | PI/NNRTI/NRTI | 13 (20%) | 3 (15%) | 1 (20%) | 17 (19%) | |
| regimen | NRTI only | 1 (2%) | 1 (5%) | 0 | 2 (2%) | |
OLA: oligonucleotide ligation assay; CS: consensus sequencing; IQR: interquartile range; NS: not significant at p = .05; ARV: antiretroviral; PI: protease inhibitor; NRTI: nucleoside reverse transcriptase inhibitor; NNRTI: non-nucleoside reverse transcriptase inhibitor therapy.
*differences between groups were not significant in analyses that were both unadjusted and adjusted for time from infection to the date of sampling.